Compare CELC & UFPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELC | UFPI |
|---|---|---|
| Founded | 2011 | 1955 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Forest Products |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.8B |
| IPO Year | 2017 | 2011 |
| Metric | CELC | UFPI |
|---|---|---|
| Price | $95.70 | $84.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $112.56 | $104.33 |
| AVG Volume (30 Days) | ★ 701.3K | 329.2K |
| Earning Date | 05-13-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.55% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.37 |
| Revenue | N/A | ★ $3,941,182,000.00 |
| Revenue This Year | N/A | $2.04 |
| Revenue Next Year | $720.19 | $5.61 |
| P/E Ratio | ★ N/A | $35.11 |
| Revenue Growth | N/A | ★ 21.62 |
| 52 Week Low | $44.42 | $77.89 |
| 52 Week High | $151.02 | $118.00 |
| Indicator | CELC | UFPI |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 38.73 |
| Support Level | $83.59 | $78.81 |
| Resistance Level | $95.59 | $84.36 |
| Average True Range (ATR) | 3.54 | 2.16 |
| MACD | 0.55 | -0.80 |
| Stochastic Oscillator | 74.11 | 14.04 |
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
UFP Industries Inc is a supplier of lumber to the manufactured housing industry. Today UFP Industries is a multibillion-dollar holding company with subsidiaries around the globe that serve three markets: retail, packaging and construction. Its business segments consist of UFP Retail Solutions, UFP Packaging, UFP Construction, All other and Corporate. It describes itself as an innovation company, a logistics company, a design company, an engineering and value-added product and solutions company.